Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M

Pyxis Oncology (NASDAQ: PYXS) reported a Q4 EPS of $(0.29), surpassing the analyst estimate of $(0.33) by 12.65%. This represents a 50.85% improvement from losses of $(0.59) per share in the same quarter last year. The company generated $11.038 million in sales during this period.